TY - JOUR
T1 - RNF168-mediated ubiquitin signaling inhibits the viability of BRCA1-null cancers
AU - Krais, John J.
AU - Wang, Yifan
AU - Bernhardy, Andrea J.
AU - Clausen, Emma
AU - Miller, Jessica A.
AU - Cai, Kathy Q.
AU - Scott, Clare L.
AU - Johnson, Neil
N1 - Funding Information:
This work was supported by NIH grant R01CA214799, Susan Komen CCRCR17499048, and OC130212 Department of Defense to N. Johnson. J. Krais was supported by an American Cancer Society - Tri State CEOs Against Cancer Postdoctoral Fellowship, PF-19-097–01–DMC, Ovarian Cancer Research Alliance and Phil and Judy Messing grant 597484, and T32 CA009035. Clovis Oncology supplied rucaparib. We are grateful to FCCC Genomics, Cell Culture and Cell Sorting facilities. We thank Dr. Daniel Durocher for providing the RNF168 and RNF8 plasmids, Dr. Thanos Halazonetis for providing the ub-H2AX plasmid, Dr. Stephen Sykes for providing the pLKO.1-RFP plasmid, and Drs. Clare Scott, Judith Balmaña, and Violeta Serra for providing PDX samples.
Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - BRCA1 gene mutations impair homologous recombination (HR) DNA repair, resulting in cellular senescence and embryonic lethality in mice. Therefore, BRCA1-deficient cancers require adaptations that prevent excessive genomic alterations from triggering cell death. RNF168-mediated ubiquitination of gH2AX at K13/15 (ub-H2AX) serves as a recruitment module for the localization of 53BP1 to DNA break sites. Here, we found multiple BRCA1-mutant cancer cell lines and primary tumors with low levels of RNF168 protein expression. Overexpression of ectopic RNF168 or a ubH2AX fusion protein induced cell death and delayed BRCA1-mutant tumor formation. Cell death resulted from the recruitment of 53BP1 to DNA break sites and inhibition of DNA end resection. Strikingly, reintroduction of BRCA1 or 53BP1 depletion restored HR and rescued the ability of cells to maintain RNF168 and ubH2AX overexpression. Thus, downregulation of RNF168 protein expression is a mechanism for providing BRCA1-null cancer cell lines with a residual level of HR that is essential for viability. Overall, our work identifies loss of RNF168 ubiquitin signaling as a proteomic alteration that supports BRCA1-mutant carcinogenesis. We propose that restoring RNF168-ub-H2AX signaling, potentially through inhibition of deubiquitinases, could represent a new therapeutic approach.
AB - BRCA1 gene mutations impair homologous recombination (HR) DNA repair, resulting in cellular senescence and embryonic lethality in mice. Therefore, BRCA1-deficient cancers require adaptations that prevent excessive genomic alterations from triggering cell death. RNF168-mediated ubiquitination of gH2AX at K13/15 (ub-H2AX) serves as a recruitment module for the localization of 53BP1 to DNA break sites. Here, we found multiple BRCA1-mutant cancer cell lines and primary tumors with low levels of RNF168 protein expression. Overexpression of ectopic RNF168 or a ubH2AX fusion protein induced cell death and delayed BRCA1-mutant tumor formation. Cell death resulted from the recruitment of 53BP1 to DNA break sites and inhibition of DNA end resection. Strikingly, reintroduction of BRCA1 or 53BP1 depletion restored HR and rescued the ability of cells to maintain RNF168 and ubH2AX overexpression. Thus, downregulation of RNF168 protein expression is a mechanism for providing BRCA1-null cancer cell lines with a residual level of HR that is essential for viability. Overall, our work identifies loss of RNF168 ubiquitin signaling as a proteomic alteration that supports BRCA1-mutant carcinogenesis. We propose that restoring RNF168-ub-H2AX signaling, potentially through inhibition of deubiquitinases, could represent a new therapeutic approach.
UR - http://www.scopus.com/inward/record.url?scp=85087530385&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-19-3033
DO - 10.1158/0008-5472.CAN-19-3033
M3 - Article
C2 - 32213544
AN - SCOPUS:85087530385
SN - 0008-5472
VL - 80
SP - 2848
EP - 2860
JO - Cancer research
JF - Cancer research
IS - 13
ER -